MedTrace Logo

Metabolomics During Testosterone Therapy

NCT01963390 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2018-04-19

No results posted yet for this study

Summary

One promising but understudied area in the field of testosterone (T) therapy is its effect on metabolism and the development of type II diabetes. Metabolomics is a powerful research tool that can detect very early signs of metabolic derangement that may lead to metabolic disease. In this observational study, investigators aim to apply metabolomics in order to better understand how T therapy influences metabolism. In a clinical population of outpatient men with T deficiency investigators will perform comprehensive clinical evaluations and also obtain blood for metabolomics. This will be done once prior to T therapy and again after 4-6 months of T therapy. Investigators hypothesize that they can detect metabolic derangements in men with T deficiency and that these derangements will improve with T therapy.

Conditions

  • Testosterone Deficiency

Interventions

DRUG

Testosterone Therapy

In this observational study we will be enrolling testosterone deficient men who intend to undergo testosterone therapy.

Sponsors & Collaborators

  • Men's Health Boston

    lead OTHER

Principal Investigators

  • Abraham Morgentaler, MD · Men's Health Boston

  • Ravi Kacker, MD · Men's Health Boston

Eligibility

Min Age
20 Years
Max Age
90 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2017-06-30
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01963390 on ClinicalTrials.gov